{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal dominant missense mutations within the gene encoding for LRRK2 predispose humans to develop Parkinson's disease (PD). Mutations in LRRK2 account for 4% of familial PD and 1% of sporadic PD patients. The study suggests that disruption of 14-3-3 binding due to reduced phosphorylation at Ser910/Ser935 may be linked to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as autosomal dominant mutations in LRRK2 leading to PD, with a focus on disrupted 14-3-3 binding and altered localization as potential contributors to pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses phosphorylation assays, 14-3-3 binding assays (overlay and co-immunoprecipitation), and cellular localization studies via confocal microscopy to assess the impact of LRRK2 mutations. These assays are employed to model the effect of mutations on protein interactions and localization relevant to PD.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays (phosphorylation, protein interaction, and localization) are relevant to PD pathogenesis as they assess critical aspects of LRRK2 function and dysfunction (14-3-3 binding and inclusion body formation) implicated in disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 is used as a normal control, and various mutants with known effects are compared. Experiments are described as performed in duplicate or repeated multiple times (e.g., kinase activity assays repeated four times).",
          "judgment": "Yes",
          "reasoning": "The paper includes wild-type LRRK2 as a normal control and mentions replicates (e.g., duplicate experiments repeated multiple times), satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study compares 41 PD-associated mutations, including well-characterized pathogenic mutations like R1441C, R1441G, Y1699C, and I2020T, which are used as reference points for reduced 14-3-3 binding and localization changes.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants (e.g., R1441C, R1441G) are used as controls to benchmark the effects on 14-3-3 binding and localization, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper does not provide specific statistical analyses or OddsPath calculations for the functional data related to 14-3-3 binding or localization for R1441C. Results are presented as qualitative reductions in phosphorylation and binding.",
          "judgment": "No",
          "reasoning": "There are no explicit statistical tests or OddsPath calculations provided for the functional impact of R1441C on 14-3-3 binding or localization.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study analyzes 41 LRRK2 mutations, with multiple pathogenic and benign-like variants compared for 14-3-3 binding and localization effects (e.g., R1441C, R1441G, Y1699C as pathogenic controls).",
          "judgment": "At least 11 controls",
          "reasoning": "The total number of variant controls (41 mutations, including multiple pathogenic ones) exceeds 10, satisfying the threshold for moderate evidence strength.",
          "next_step_or_outcome": "Assign PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1441C is rated as PS3_moderate due to clear evidence of reduced Ser910/Ser935 phosphorylation and 14-3-3 binding, leading to accumulation in cytoplasmic pools resembling inclusion bodies, which is consistent with a pathogenic mechanism in PD. The assessment is supported by the use of multiple variant controls and repeated experiments, though lacking specific statistical analyses."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal dominant missense mutations within LRRK2 predispose humans to develop PD. The study suggests that disruption of 14-3-3 binding due to reduced phosphorylation at Ser910/Ser935 may be linked to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as autosomal dominant mutations in LRRK2 leading to PD, focusing on disrupted 14-3-3 binding and localization as potential contributors to pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses phosphorylation assays, 14-3-3 binding assays, and cellular localization studies to assess the impact of LRRK2 mutations on protein interactions and localization relevant to PD.",
          "judgment": "Yes",
          "reasoning": "The assays (phosphorylation, protein interaction, and localization) are relevant to PD pathogenesis as they evaluate critical aspects of LRRK2 dysfunction implicated in disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 is used as a normal control, and experiments are described as performed in duplicate or repeated multiple times.",
          "judgment": "Yes",
          "reasoning": "The paper includes wild-type LRRK2 as a control and mentions replicates, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study compares 41 PD-associated mutations, including well-characterized pathogenic mutations like R1441G, R1441C, Y1699C, and I2020T.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants are used as controls to benchmark effects on 14-3-3 binding and localization, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "No specific statistical analyses or OddsPath calculations are provided for the functional data related to 14-3-3 binding or localization for R1441G.",
          "judgment": "No",
          "reasoning": "There are no explicit statistical tests or OddsPath calculations provided for R1441G.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study analyzes 41 LRRK2 mutations, with multiple pathogenic and benign-like variants compared.",
          "judgment": "At least 11 controls",
          "reasoning": "The total number of variant controls exceeds 10, satisfying the threshold for moderate evidence strength.",
          "next_step_or_outcome": "Assign PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1441G is rated as PS3_moderate due to evidence of abolished Ser910/Ser935 phosphorylation and 14-3-3 binding, leading to accumulation in cytoplasmic pools, consistent with a pathogenic mechanism in PD. The assessment is supported by multiple variant controls and repeated experiments, though lacking specific statistical analyses."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441H"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal dominant missense mutations within LRRK2 predispose humans to develop PD, with disruption of 14-3-3 binding due to reduced phosphorylation at Ser910/Ser935 potentially linked to PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as LRRK2 mutations leading to PD, focusing on disrupted 14-3-3 binding and localization."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Phosphorylation assays, 14-3-3 binding assays, and cellular localization studies are used to assess LRRK2 mutations.",
          "judgment": "Yes",
          "reasoning": "The assays are relevant to PD pathogenesis, evaluating critical aspects of LRRK2 dysfunction.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 is used as a control, and experiments are performed in duplicate or repeated multiple times.",
          "judgment": "Yes",
          "reasoning": "Criteria for basic controls and replicates are met.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "41 PD-associated mutations, including pathogenic mutations like R1441H, are compared.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants are used as controls, meeting the criteria.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "No specific statistical analyses or OddsPath calculations are provided for R1441H.",
          "judgment": "No",
          "reasoning": "Lack of statistical tests or OddsPath calculations.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "41 LRRK2 mutations are analyzed as controls.",
          "judgment": "At least 11 controls",
          "reasoning": "The number of variant controls exceeds 10.",
          "next_step_or_outcome": "Assign PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1441H is rated as PS3_moderate due to reduced Ser910/Ser935 phosphorylation and 14-3-3 binding, leading to accumulation in cytoplasmic pools, consistent with a pathogenic mechanism in PD, supported by multiple controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations predispose to PD, with disruption of 14-3-3 binding potentially linked to pathogenesis.",
          "judgment": "Yes",
          "reasoning": "Clear definition of disease mechanism involving LRRK2 mutations and 14-3-3 binding disruption."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Phosphorylation, binding, and localization assays are used.",
          "judgment": "Yes",
          "reasoning": "Assays are relevant to PD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 as control, experiments repeated multiple times.",
          "judgment": "Yes",
          "reasoning": "Criteria for controls and replicates are met.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "41 mutations, including Y1699C, are compared.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants used as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "No statistical analyses or OddsPath for Y1699C.",
          "judgment": "No",
          "reasoning": "Lack of statistical data.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "41 mutations analyzed.",
          "judgment": "At least 11 controls",
          "reasoning": "Exceeds 10 controls threshold.",
          "next_step_or_outcome": "Assign PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 Y1699C is rated as PS3_moderate due to abolished Ser910/Ser935 phosphorylation and 14-3-3 binding, leading to cytoplasmic pool accumulation, supported by multiple controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations linked to PD, with 14-3-3 binding disruption as a potential mechanism.",
          "judgment": "Yes",
          "reasoning": "Clear disease mechanism defined."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Phosphorylation, binding, and localization assays used.",
          "judgment": "Yes",
          "reasoning": "Assays relevant to PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type control and repeated experiments.",
          "judgment": "Yes",
          "reasoning": "Criteria met.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "41 mutations, including I2020T.",
          "judgment": "Yes",
          "reasoning": "Pathogenic variants as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "No statistical data for I2020T.",
          "judgment": "No",
          "reasoning": "Lack of statistical analysis.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "41 mutations analyzed.",
          "judgment": "At least 11 controls",
          "reasoning": "Exceeds threshold.",
          "next_step_or_outcome": "Assign PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 I2020T is rated as PS3_moderate due to abolished Ser910/Ser935 phosphorylation and 14-3-3 binding, leading to cytoplasmic pool accumulation, supported by multiple controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations predispose to PD, with increased kinase activity as a potential pathogenic mechanism for G2019S.",
          "judgment": "Yes",
          "reasoning": "Disease mechanism defined as increased kinase activity for G2019S leading to PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Kinase activity assays using LRRKtide peptide substrate are used to measure catalytic activity of LRRK2 mutants.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays are directly relevant to the proposed mechanism of increased activity in PD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 as control, kinase assays performed in duplicate for three experiments.",
          "judgment": "Yes",
          "reasoning": "Wild-type control and replicates are mentioned, meeting criteria.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "41 mutations compared, including other pathogenic variants with increased activity (e.g., R1728H, T2031S).",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants with altered kinase activity are used as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Kinase activity reported as approximately 3-fold higher for G2019S compared to wild-type, with means +/- S.E.M. provided for duplicate assays over three experiments.",
          "judgment": "Yes",
          "reasoning": "Quantitative data with error measures are provided, sufficient to infer strength of evidence.",
          "next_step_or_outcome": "Proceed to Step 4c"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "G2019S shows a 3-fold increase in kinase activity compared to wild-type LRRK2.",
          "judgment": "Moderate strength",
          "reasoning": "A 3-fold increase in activity, while significant, falls within the moderate range for pathogenic evidence (OddsPath equivalent inferred as >4.3 but not very high), as per ACMG guidelines.",
          "next_step_or_outcome": "Assign PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S is rated as PS3_moderate due to a significant 3-fold increase in kinase activity, consistent with a pathogenic mechanism in PD, supported by quantitative data and multiple controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1728"
        },
        "variant_string_id": "LRRK2 R1728H"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations predispose to PD, with increased kinase activity as a potential mechanism.",
          "judgment": "Yes",
          "reasoning": "Disease mechanism defined as increased kinase activity for certain LRRK2 mutations."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Kinase activity assays using LRRKtide peptide substrate.",
          "judgment": "Yes",
          "reasoning": "Assays relevant to PD mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type control, assays in duplicate for three experiments.",
          "judgment": "Yes",
          "reasoning": "Criteria met.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "41 mutations, including pathogenic variants with increased activity.",
          "judgment": "Yes",
          "reasoning": "Pathogenic variants as controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "2-fold increase in kinase activity for R1728H, with means +/- S.E.M.",
          "judgment": "Yes",
          "reasoning": "Quantitative data provided.",
          "next_step_or_outcome": "Proceed to Step 4c"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "2-fold increase in kinase activity.",
          "judgment": "Supporting strength",
          "reasoning": "A 2-fold increase aligns with supporting evidence (OddsPath >2.0 but â‰¤4.3).",
          "next_step_or_outcome": "Assign PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1728H is rated as PS3_supporting due to a 2-fold increase in kinase activity, consistent with a pathogenic mechanism, supported by quantitative data."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "T",
          "alt": "S",
          "position": "2031"
        },
        "variant_string_id": "LRRK2 T2031S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations predispose to PD, with increased kinase activity as a mechanism.",
          "judgment": "Yes",
          "reasoning": "Mechanism defined."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Kinase activity assays used.",
          "judgment": "Yes",
          "reasoning": "Relevant assays.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type control, assays repeated.",
          "judgment": "Yes",
          "reasoning": "Criteria met.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "41 mutations compared.",
          "judgment": "Yes",
          "reasoning": "Pathogenic controls used.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "4-fold increase in kinase activity for T2031S, with means +/- S.E.M.",
          "judgment": "Yes",
          "reasoning": "Quantitative data provided.",
          "next_step_or_outcome": "Proceed to Step 4c"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "4-fold increase in kinase activity.",
          "judgment": "Moderate strength",
          "reasoning": "A 4-fold increase aligns with moderate evidence (OddsPath >4.3).",
          "next_step_or_outcome": "Assign PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 T2031S is rated as PS3_moderate due to a significant 4-fold increase in kinase activity, consistent with a pathogenic mechanism, supported by quantitative data."
    }
  ]
}